In Pfenex’s fourth-quarter 2017 investor call, Evert Schimmelpennink, CEO, president, secretary, and director, hinted that Pfenex may be ready to resume work on 2 biosimilar candidates whose programs had been on hiatus.
In Pfenex’s fourth-quarter 2017 investor call this month, Evert Schimmelpennink, CEO, president, secretary, and director, hinted that Pfenex may be ready to resume work on 2 biosimilar candidates whose programs had been on hiatus.
Previously, in its 2017 third-quarter call held in November 2017, Pfenex announced the company’s “decision to pause development activities” for PF582, a ranibizumab biosimilar referencing Lucentis, and PF529, a pegfilgrastim biosimilar referencing Neulasta, after a strategic review of both costs and development timelines for the drugs.
In this month’s call, Schimmelpennink said, “We continue to believe that the most prudent path for the development is a collaboration with a strategic development partner. As that business development process continues, we continue to seek partners with whom we would advance those programs.” Halting development of the 2 programs lowered research and development costs to $7.2 million in the fourth quarter of 2017 compared with $10.7 million in the same period in 2016, said Schimmelpennink.
Pfenex previously partnered with Hospira on the ranibizumab biosimilar candidate, but after Pfizer acquired Hospira in 2016, Pfizer terminated the collaboration.
Pfenex did not address its progress on the third biosimilar its pipeline, a pegaspargase candidate referencing Oncaspar. The company’s lead products include PF708, a “therapeutic equivalent candidate” to teriparatide (Forteo) for the treatment of osteoporosis, and 2 novel anthrax vaccine candidates, Px563L and RPA563, which it is developing through a contract with the US government.
In addition, the company continues to develop hematology and oncology products in collaboration with Jazz Pharmaceuticals. Under Pfenex’s agreement with Jazz, Pfenex received upfront and option payment totaling $15 million, and may be eligible to receive payments of up to $166 million based on achievements of certain development, regulatory, and sales milestones.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes
April 24th 2025Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.